Sherry Dekeyser
Psychiatry · Ponte Vedra, FLNPI 1518913540
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 28.7% of the total. Reporting peaked in 2023 at $1,097 and has fallen 69.8% since, to $331 in 2025.
Across 226 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$449
- Lundbeck LLC$437
- Vanda Pharmaceuticals Inc.$349
- Axsome Therapeutics, Inc.$343
- Alkermes, Inc.$317
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,78699%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,391 |
| Otsuka America Pharmaceutical, Inc. | 19 | $449 |
| Lundbeck LLC | 20 | $437 |
| Vanda Pharmaceuticals Inc. | 14 | $349 |
| Axsome Therapeutics, Inc. | 9 | $343 |
| Alkermes, Inc. | 10 | $317 |
| Johnson & Johnson | 10 | $197 |
| Neurocrine Biosciences, Inc. | 10 | $197 |
| Jazz Pharmaceuticals Inc. | 8 | $170 |
| Supernus Pharmaceuticals, Inc. | 12 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $149 |
| Teva Pharmaceuticals USA, Inc. | 5 | $120 |
| Bausch Health US, LLC | 6 | $97 |
| Almatica Pharma LLC | 5 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $78 |
| Corium, LLC | 4 | $61 |
| Ironshore Pharmaceuticals Inc. | 3 | $61 |
| Biogen | 2 | $41 |
| Eisai Inc. | 2 | $38 |
| Neos Therapeutics, LP | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Noven Pharmaceuticals, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,846 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $453 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Ponte Vedra
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.